561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19

BACKGROUND: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report safety of RDV in patients with moderate COVID-19. METHODS: We conducted an open-label, phase 3 trial (NCT04252664) in hospitalized patients with confirmed SARS...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Open Forum Infect Dis
Asıl Yazarlar: Criner, Gerard J, Ahn, Mi Young, Huhn, Gregory, Subramanian, Aruna, Lumbreras, Carlos, Schmiedel, Stefan, Hyland, Robert H, Suri, Vithika, Cao, Huyen, Wang, Hongyuan, SenGupta, Devi, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Chen, Yao-Shen, Günthard, Huldrych, Sanz-Moreno, D Jose, Aberg, Judith A, Nicastri, Emanuele, Tsang, Owen Tak-Yin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Poster Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777368/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.755
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller